CB1 receptor levels increased in the brain reward center during morphine withdrawal in rats
Rats undergoing morphine withdrawal showed increased CB1 receptor expression in the nucleus accumbens, a brain reward center, across all withdrawal phases, and blocking these receptors reduced drug-seeking behavior.
Quick Facts
What This Study Found
Researchers examined CB1 cannabinoid receptor expression in the nucleus accumbens core (a key brain reward region) of rats during acute (1 day), latent (3 days), and chronic (3 weeks) morphine withdrawal. CB1 receptor expression was significantly increased at all three time points compared to controls.
Electron microscopy revealed that CB1 receptors were primarily located on presynaptic terminals forming inhibitory (symmetrical) synapses. Both the number of CB1-positive terminals and the density of receptor particles at these terminals increased during withdrawal.
When researchers injected the CB1 receptor blocker rimonabant directly into the nucleus accumbens, it reduced conditioned place preference (a measure of drug-seeking behavior) during morphine withdrawal.
Key Numbers
CB1 receptor expression was elevated at 1 day, 3 days, and 3 weeks of morphine withdrawal. Increased receptor density was observed at inhibitory presynaptic terminals. Rimonabant infusion into the nucleus accumbens reduced conditioned place preference.
How They Did This
Rats were exposed to morphine to establish conditioned place preference, then underwent withdrawal for 1 day, 3 days, or 3 weeks. CB1 receptor expression in the nucleus accumbens core was assessed using immunofluorescence microscopy and immunoelectron microscopy. The functional role of CB1 receptors was tested by infusing the antagonist rimonabant into the nucleus accumbens during withdrawal.
Why This Research Matters
Relapse is one of the biggest challenges in addiction treatment. This study identified the endocannabinoid system in the nucleus accumbens as persistently altered during opioid withdrawal, suggesting it may contribute to the drug-seeking behavior that underlies relapse.
The Bigger Picture
This study connects the endocannabinoid and opioid systems in the context of addiction and relapse. The persistent upregulation of CB1 receptors across all withdrawal phases suggests that the endocannabinoid system may play an ongoing role in maintaining drug-seeking motivation, not just during acute withdrawal.
What This Study Doesn't Tell Us
This was an animal study in rats, and findings may not directly translate to humans. Morphine withdrawal was studied, not cannabis withdrawal. The forced morphine exposure paradigm differs from human patterns of drug use. Only one brain region was examined.
Questions This Raises
- ?Does a similar CB1 receptor upregulation occur in the human nucleus accumbens during opioid withdrawal?
- ?Would CB1 receptor blockers reduce relapse rates in human addiction treatment?
- ?Is this endocannabinoid system change specific to opioid withdrawal, or does it occur with other drugs?
Trust & Context
- Key Stat:
- CB1 receptors elevated across all three phases of morphine withdrawal
- Evidence Grade:
- Well-conducted animal study with multiple methodologies, but findings are preclinical and require human translation.
- Study Age:
- Published in 2013.
- Original Title:
- Increased expression of cannabinoid receptor 1 in the nucleus accumbens core in a rat model with morphine withdrawal.
- Published In:
- Brain research, 1531, 102-12 (2013)
- Authors:
- Yuan, Wei-Xin, Heng, Li-Jun, Ma, Jie, Wang, Xing-Qin, Qu, Li-Juan, Duan, Li, Kang, Jun-Jun, Chen, Liang-Wei, Gao, Guo-Dong
- Database ID:
- RTHC-00754
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
How are the cannabinoid and opioid systems connected in addiction?
This study found that CB1 cannabinoid receptors in a key brain reward region increased during opioid withdrawal, and blocking them reduced drug-seeking behavior. This suggests the endocannabinoid system may help maintain drug cravings during withdrawal.
Could cannabinoid receptor blockers help treat opioid addiction?
This animal study showed that infusing a CB1 blocker (rimonabant) into the nucleus accumbens reduced drug-seeking behavior during morphine withdrawal. However, translating this to human treatment would require extensive further research.
Read More on RethinkTHC
- THC-amygdala-anxiety-brain
- anandamide-weed-withdrawal
- cannabinoid-receptors-recovery-time
- cannabis-developing-brain-teenagers
- cant-enjoy-anything-without-weed
- dopamine-recovery-after-quitting-weed
- endocannabinoid-system-explained-simply
- endocannabinoid-system-withdrawal
- nervous-system-weed-withdrawal-fight-flight
- teen-weed-use-under-18-effects-brain
- thc-brain-withdrawal
- thc-prefrontal-cortex-brain-effects
- weed-cortisol-stress-hormones
- weed-memory-loss-recovery
- weed-motivation-amotivational-syndrome
- weed-nervous-system-effects
- weed-reward-system-brain
- why-does-weed-make-you-laugh-thc-humor
Cite This Study
https://rethinkthc.com/research/RTHC-00754APA
Yuan, Wei-Xin; Heng, Li-Jun; Ma, Jie; Wang, Xing-Qin; Qu, Li-Juan; Duan, Li; Kang, Jun-Jun; Chen, Liang-Wei; Gao, Guo-Dong. (2013). Increased expression of cannabinoid receptor 1 in the nucleus accumbens core in a rat model with morphine withdrawal.. Brain research, 1531, 102-12. https://doi.org/10.1016/j.brainres.2013.07.047
MLA
Yuan, Wei-Xin, et al. "Increased expression of cannabinoid receptor 1 in the nucleus accumbens core in a rat model with morphine withdrawal.." Brain research, 2013. https://doi.org/10.1016/j.brainres.2013.07.047
RethinkTHC
RethinkTHC Research Database. "Increased expression of cannabinoid receptor 1 in the nucleu..." RTHC-00754. Retrieved from https://rethinkthc.com/research/yuan-2013-increased-expression-of-cannabinoid
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.